Liquidia (LQDA) Q1 Profitability Surge Tests Bearish Margin Narratives

Simply Wall St.

05/13

AdvertisementLiquidia (LQDA) Q1 2026: Earnings Snapshot Liquidia (LQDA) has just posted a punchy Q1 2026 print, with revenue of US$132.9 million and basic EPS of US$0.60, supported by net income of US...

网页链接

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2635894767"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2635894767\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2635894767?lang=zh_CN&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","is_english":true,"pubTime":"2026-05-13 18:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2635894767","market":"sg","top_or_hot":-1,"title":"Liquidia (LQDA) Q1 Profitability Surge Tests Bearish Margin Narratives","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementLiquidia (LQDA) Q1 2026: Earnings Snapshot Liquidia (LQDA) has just posted a punchy Q1 2026 print, with revenue of US$132.9 million and basic EPS of US$0.60, supported by net income of US...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lqda/liquidia/news/liquidia-lqda-q1-profitability-surge-tests-bearish-margin-na\">网页链接</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Liquidia (LQDA) Q1 Profitability Surge Tests Bearish Margin Narratives</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLiquidia (LQDA) Q1 Profitability Surge Tests Bearish Margin Narratives\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-13 18:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lqda/liquidia/news/liquidia-lqda-q1-profitability-surge-tests-bearish-margin-na><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementLiquidia (LQDA) Q1 2026: Earnings Snapshot Liquidia (LQDA) has just posted a punchy Q1 2026 print, with revenue of US$132.9 million and basic EPS of US$0.60, supported by net income of US...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lqda/liquidia/news/liquidia-lqda-q1-profitability-surge-tests-bearish-margin-na\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LQDA","symbol_name":"Liquidia Technologies Inc","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lqda/liquidia/news/liquidia-lqda-q1-profitability-surge-tests-bearish-margin-na","article_id":"2635894767","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lqda/liquidia/news/liquidia-lqda-q1-profitability-surge-tests-bearish-margin-na","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2635894767","pubTimestamp":1778669842,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Liquidia (LQDA) Q1 2026: Earnings Snapshot\nLiquidia (LQDA) has just posted a punchy Q1 2026 print, with revenue of US$132.9 million and basic EPS of US$0.60, supported by net income of US$52.9 million. The company has seen revenue move from US$3.1 million and a loss of US$38.4 million in Q1 2025, through US$2.9 million and a loss of US$38.5 million in Q4 2024, to US$132.9 million and net income of US$52.9 million in the latest quarter. Over the same period, TTM EPS has shifted from a loss of...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LQDA":"Liquidia Technologies Inc","BK4007":"制药"},"translate_title":"Liquidia(LQDA)第一季度盈利能力飙升测试看跌利润率叙述","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LQDA":1.5},"content_text":"AdvertisementLiquidia (LQDA) Q1 2026: Earnings Snapshot Liquidia (LQDA) has just posted a punchy Q1 2026 print, with revenue of US$132.9 million and basic EPS of US$0.60, supported by net income of US$52.9 million. The company has seen revenue move from US$3.1 million and a loss of US$38.4 million in Q1 2025, through US$2.9 million and a loss of US$38.5 million in Q4 2024, to US$132.9 million and net income of US$52.9 million in the latest quarter. Over the same period, TTM EPS has shifted from a loss of US$1.63 in Q4 2024 to a profit of US$0.26 in Q1 2026, setting up a story where margins are now firmly in focus for investors assessing how durable this profitability profile really is. See our full analysis for Liquidia. With the headline numbers on the table, the next step is to see how this earnings turn lines up with the widely followed growth and risk narratives around Liquidia and where the latest results start to challenge those stories. See what the community is saying about Liquidia NasdaqCM:LQDA Revenue & Expenses Breakdown as at May 2026 TTM swing from US$136.6m loss to US$22.3m profit  On a trailing twelve month view, net income moved from a loss of US$136.6 million in Q1 2025 to a profit of US$22.3 million in Q1 2026, while TTM EPS shifted from a loss of US$1.68 to a profit of US$0.26 over the same period. Bulls point out that moving into profitability lines up with their view that YUTREPIA and the broader treprostinil platform can support higher margins over time, yet:\n     They reference forecasts for earnings growth of about 30.2% per year and revenue growth of about 24.9% per year, which are assessed against this US$288.1 million TTM revenue base rather than the much smaller revenue levels seen a year earlier. They also highlight that bullish scenarios assume profit margins eventually settling above 40%, so investors can compare that to the current TTM profit of US$22.3 million to judge how far along the margin story is.    Bulls argue this kind of earnings shift is exactly what long term holders were waiting for, and that the latest narrative shows how they think it could continue: 🐂 Liquidia Bull Case Q1 2026 profit of US$52.9m tests bearish caution  In the latest single quarter, Liquidia reported net income of US$52.9 million in Q1 2026 compared with a reported loss of US$41.6 million in Q2 2025, with quarterly revenue over that span ranging from US$8.8 million to US$132.9 million. Bears worry that early YUTREPIA demand could be front loaded and that future revenue might not keep pace with current expectations, and the recent results give them a few pressure points to watch:\n     They flag that bearish scenario work still allows for annual revenue growth of around 100.2% over the next three years, yet that view is paired with only modest margins of about 4.2%, so a US$52.9 million quarterly profit puts the current margin picture ahead of that cautious path for now. They also point out that even under these cautious assumptions, the business would need to support a relatively high future P/E, so the size and consistency of profits like this quarter become central to whether that level of valuation risk feels acceptable.    Skeptics suggest the recent jump in profit might prove harder to sustain than bulls expect, and the cautious narrative lays out the scenarios they focus on: 🐻 Liquidia Bear Case Rich 17.5x P/S against US$56.60 share price  The stock trades on a P/S of 17.5x versus a peer average of 7.4x and a US Pharmaceuticals industry average of 4.8x, while the current share price of US$56.60 also sits far below the DCF fair value figure of US$297.32. What stands out is how this valuation mix creates a tension between bullish and bearish views, using the same data points:\n     Supporters of the bullish case see the low share price versus the US$297.32 DCF fair value and the shift to a US$22.3 million TTM profit as signals that the market may be underpricing potential cash flows, even with a higher than average P/S. On the other hand, cautious investors highlight the 17.5x P/S, the recent share price volatility, and the reported insider selling in the past three months as reasons to question whether current expectations already bake in a lot of good news despite that DCF gap.    Next Steps To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Liquidia on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves. With sentiment clearly split between opportunity and risk, now is a good time to look through the numbers yourself and decide what really matters for your portfolio. You can start with 3 key rewards and 2 important warning signs See What Else Is Out There Liquidia combines a rich 17.5x P/S multiple, recent share price volatility, and insider selling, which leaves some investors uneasy about valuation risk and future consistency. If that mix of high expectations and uncertainty feels a bit too intense, you can quickly compare it with companies screened for 69 resilient stocks with low risk scores to find ideas that may better match your comfort level.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}